中文摘要：

黃嘌呤氧化還原酶與癌癥有關。然而，其可互變的兩種形式——黃嘌呤脫氫酶（XDH）和黃嘌呤氧化酶（XO）在腫瘤形成過程中的作用尚不清楚。在本研究中，我們生成了XDH穩(wěn)定型和XO鎖定型敲入（ki）小鼠以探討這個問題。腫瘤移植后，XO ki小鼠的腫瘤生長顯著高于野生型（WT）和XDH ki小鼠。血液系統(tǒng)中XO表達導致了這一效果。荷蘭Liposoma氯膦酸鹽脂質體清除劑清除巨噬細胞后，腫瘤生長減緩。在WT小鼠中采用XO ki巨噬細胞移植會增加腫瘤生長。體外實驗顯示，XO ki巨噬細胞產生更高水平的活性氧（ROS），這導致腫瘤中調節(jié)性T細胞（Tregs）增多。體內阻斷ROS可減緩腫瘤生長?？傮w而言，這些結果表明XO/XDH的平衡在腫瘤發(fā)展的免疫監(jiān)控中起重要作用。特異性抑制XO形式的策略可能在控制癌癥生長中具有價值。

英文摘要：

Xanthine oxidoreductase has been implicated in cancer. Nonetheless, the role played by its two convertible forms, xanthine dehydrogenase (XDH) and oxidase (XO) during tumorigenesis is not understood. Here we produce XDH-stable and XO-locked knock-in (ki) mice to address this question. After tumor transfer, XO ki mice show strongly increased tumor growth compared to wild type (WT) and XDH ki mice. Hematopoietic XO expression is responsible for this effect. After macrophage depletion, tumor growth is reduced. Adoptive transfer of XO-ki macrophages in WT mice increases tumor growth. In vitro, XO ki macrophages produce higher levels of reactive oxygen species (ROS) responsible for the increased Tregs observed in the tumors. Blocking ROS in vivo slows down tumor growth. Collectively, these results indicate that the balance of XO/XDH plays an important role in immune surveillance of tumor development. Strategies that inhibit the XO form specifically may be valuable in controlling cancer growth.

論文信息：

論文題目：Targeted knock-in mice expressing the oxidase-fixed form of xanthine oxidoreductase favor tumor growth

期刊名稱：Nature Communications

時間期卷：10, Article number:4904(2019)

在線時間：2019年10月28日

DOI： doi.org/10.1038/s41467-019-12565-z

產品信息：

貨號：CP-005-005

規(guī)格：5ml+5ml

品牌：Liposoma

產地：荷蘭

名稱：Clodronate Liposomes&Control liposomes

辦事處：Target Technology(靶點科技)

Clodronate Liposomes氯膦酸鹽脂質體清除皮下接種CMT93小鼠結直腸癌細胞腫瘤細胞模型巨噬細胞，荷蘭Liposoma巨噬細胞清除劑ClodronateLiposomes見刊于Nature Communications：表達固定氧化酶形式黃嘌呤氧化還原酶的定向敲入小鼠有利于腫瘤生長。

Liposoma巨噬細胞清除劑Clodronate Liposomes氯膦酸二鈉脂質體清除腫瘤模型巨噬細胞的材料和方法：

In vivo macrophage depletion

Liposome-encapsulated clodronate (dichloromethylene bisphosphonate) or liposome-PBS were provided by LIPOSOMA, Amsterdam, Netherlands, and were prepared according to the manufacturer’s protocol. Mice were daily injected intraperitoneally with 200?μL of a clodronate-loaded liposome suspension 4 times starting 3 days before tumor injection. Control mice were injected with 200?μL PBS-loaded liposomes using the same schedule.

材料和方法文獻截圖：